ISSN 1496-3876 FALL 2022 VOLUME 26 NUMBER 3
CMPT - A vision for the future
Since taking on these leadership roles in June, Dr. Perrone has been working with her team on several initiatives which are aimed at ensuring program sustainability and enabling growth.
Issues with Piperacillin-Tazobactam (PIP-TAZ) Breakpoints
In CMPT Challenge M221-5 (July, 2022), a simulated blood culture with Acinetobacter baumanii, antimicrobial susceptibilities for piperacillin-tazobactam (Pip-Taz) were ungraded due to lack of consensus by the participants. It was unknown what breakpoints were being used for reporting this agent. This short article will attempt to provide some direction going forward regarding changes in breakpoints so that laboratories can provide an accurate and clinically relevant test result for this agent.
Professional Development for Laboratory Staff
New and exciting course offered in partnership with POLQM: